Expand ALLR Menu
ALLR MENU

ALLR Latest Press Releases

-- September 15, 2026 --

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development Globe Newswire 8:00 AM

-- September 11, 2026 --

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement Globe Newswire 8:00 AM

-- August 14, 2026 --

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign Globe Newswire 8:00 AM

-- July 7, 2026 --

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP Testing for FDA Registration Globe Newswire 8:00 AM

-- June 30, 2026 --

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP Companion Diagnostic Globe Newswire 8:00 AM

-- June 18, 2026 --

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 Globe Newswire 8:00 AM

-- May 15, 2026 --

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers Globe Newswire 4:30 PM

-- May 8, 2026 --

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm Globe Newswire 8:45 AM

-- May 5, 2026 --

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign Globe Newswire 8:00 AM

-- April 27, 2026 --

Allarity Therapeutics Announces that the Stenoparib DRP Test Has Received a Notice of Allowance from the US Patent and Trademark Office Globe Newswire 8:00 AM

-- April 21, 2026 --

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes